The list goes on and on and on. So, we provide these fantastic reports. But let’s get more into the actual opportunities from a business point of view. So, as you all know, we have been historically a direct-to-consumer seller of whole genome sequencing. We have completely revamped our marketing campaigns, which is all going to roll out in the next few months. And at the same time, we’ve built out a lab. The reason we built out the lab is because we started going to these genomics conferences. And there are all these businesses that never did whole genome sequencing, but they’re directly related to it through the healthcare systems and they’re like, “Oh my God, we have to offer whole genome sequencing to our customers.” So, we have a lab in New York, so your specimen doesn’t have to leave the country.
We have some of the best pricing not only in the country but in the world. This all started because we’ve been in the business for six years and we have the best relationships. There are companies, genomics companies in other countries with some of the best equipment and consumables in the world that are willing to partner with us and build with us because they want a presence in the United States, and we are the first lab in the country to have some of their highly-efficient, high-capacity equipment. It gives us the ability to work with large businesses and potentially offer them high capacity, low price, whole genome sequencing. A lot of these businesses have never offered it to their customers before. So, when we went to these genomics conferences, we were like, “Oh my God, this is such a big opportunity.” We made the strategic decision to exit our initiative with the clinical lab business.
We could have been very successful in the clinical lab business, but maybe in a few years, it would be a $10 million or $20 million business and it could be worth $30 million or $40 million, whatever it is. We were going to do it. There’s a real opportunity there. But the opportunity at Nebula Genomics is 10 times that. And so, we have all these businesses that we’re in late-stage negotiations with that could literally explode our business going forward. So, as I mentioned, we used to have 300 reports and then 325 reports, now 340 reports and growing. The labs around the world, most of them pale in comparison. We’re now getting reports that there are other labs, even in this country, that are providing whole genome sequencing. They promise a certain turnaround time on their website.
There’s no reality to it. Furthermore, they advertise certain prices on their website, but there’s no reality to that either, because then to buy the reports, you have to buy individual reports. We provide 300 to 340 reports. They’ll provide 10 reports. When you add their 10 reports to their cost of whole genome sequencing, it turns out to be dramatically greater than our offer. So, we are price competitive, we have highly efficient turnaround times that we’re responsible, reliable. We have this fantastic proprietary reporting system. So, the sky is the limit. So, Jason Karkus now became president of Nebula. What he did with COVID testing, he’s now doing with Nebula. And I can tell you that the response has been enormous. We announced the first deal today.
We didn’t get too specific about it. We just signed the contract literally, I don’t know, 24, 48 hours ago. There are more coming. We will get into more details in some of the other contracts we’re working on. Suffice it to say some are significant. Some are very significant. One example, one contract in late stages, we’re talking about a $10 million to $20 million run rate of revenues the first year and then growing from there. Another one, the numbers could be even dramatically larger. We’re talking to a telemedicine platform with 2,000 physicians and 6 million to 8 million patients. Do you understand if they turn on the switch and say, go to these 2,000 — the owner says, we’re going to reach out to these 2,000 physicians the next time you meet with your patient, suggest to them to order a Nebula Genomics test kit.
Do you have any idea how large this could be? This is what we’re working on going forward. So, that’s a little bit about the Nebula roadmap. I can discuss more in the Q&A. I already mentioned our BE-Smart test a little bit. We have this cutting edge test. I’ll talk more about it in the Q&A if somebody asks the question. The bottom line, as I said, GERD becomes Barrett’s esophagus, which becomes esophageal cancer. We have a test that will tell you — now understand when you get an endoscopy, they take 79 tissue biopsies out of your esophagus. If two different pathologists study the same specimen under the same microscope, one will tell you have esophageal cancer, the other will tell you don’t. It’s incredibly inexact science. Meanwhile, it’s one of the deadliest cancers.
80% to 90% of people, once diagnosed, will die of esophageal cancer. It’s as deadly as right up there with pancreatic cancer. So, it’s amazing how deadly it is and how inexact the science is for diagnosing it. We have a test that will tell you with 99% certainty whether or not you have esophageal cancer right now or not. But what’s interesting is we met with the heads of many of the leading insurance companies. They said what’s more important to them is telling them whether a patient is at high risk or low risk. So, we’ve isolated the eight key proteins that are responsible for when they shift that give you the signal that you’re developing esophageal cancer. This is proprietary to us to our test. And so, what we’re doing right now in all the studies we’ve been doing, we’ve been going back and going through all the studies that have been done over the last number of years, and we’re actually creating a green, yellow, orange, red strike zone for our tests for reporting so that if you’re green, all systems clear, you don’t have esophageal cancer, you’re at low risk or no risk at all, you don’t have to get an endoscopy every year.
